Position in ARGX
as of Jun 30, 2026
· filed Aug 21, 2026
Position Value
$4,032,088
+$745,233 QoQ
Shares Held
4,346
-3.4% QoQ
Ownership
0.007%
of shares outstanding
% of Portfolio
0.85%
of 13F equity value
Holder Rank
#160
of 504 holders
Holding Since
Jun 2024
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HARVEY CAPITAL MANAGEMENT INC holds $42,449,117 across 7 Biotechnology names. ARGX ranks #5 (9.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | HALO |
Halozyme Therapeutics, Inc.
|
146,113 | $11,436,264 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
138,835 | $10,340,430 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
26,913 | $6,485,225 | |
| 4 | CYTK |
Cytokinetics Inc
|
68,275 | $5,816,347 | |
| 5 | ARGX |
Argenx SE
This page
|
4,346 | $4,032,088 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,975 | $3,102,111 | |
| 7 | ABVX |
Abivax S.A.
|
9,280 | $1,236,652 |
All Filings in ARGX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,032,088 | 4,346 | Shares | Sole | 2026-08-21 | |
| 2026-03-31 | $3,286,855 | 4,501 | Shares | Sole | 2026-05-11 | |
| 2025-03-31 | $6,554,904 | 11,075 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $7,110,015 | 11,561 | Shares | Sole | 2025-01-29 | |
| 2024-09-30 | $7,640,075 | 14,094 | Shares | Sole | 2024-10-29 | |
| 2024-06-30 | $6,071,734 | 14,119 | Shares | Sole | 2024-07-22 | |
| No filing history on record for this holder in this stock. | ||||||